Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced the approval of inducement grants for 33 new employees by its Board of Directors on July 25, 2024. These grants, made under NASDAQ Listing Rule 5635(c)(4), are outside the company's stockholder-approved equity incentive plans. The grants collectively allow the new employees to receive up to 60,900 restricted stock units. These units will vest annually over a four-year period, providing a long-term incentive for the new hires to align their interests with the company's performance.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha annunciato l'approvazione di assegnazioni incentivanti per 33 nuovi dipendenti da parte del suo Consiglio di Amministrazione il 25 luglio 2024. Queste assegnazioni, effettuate ai sensi della Regola di Quotazione NASDAQ 5635(c)(4), sono al di fuori dei piani di incentivazione patrimoniale approvati dagli azionisti dell'azienda. Le assegnazioni consentono collettivamente ai nuovi dipendenti di ricevere fino a 60.900 unità azionarie vincolate. Queste unità matureranno annualmente su un periodo di quattro anni, offrendo un incentivo a lungo termine per i nuovi assunti affinché allineino i propri interessi con le performance dell'azienda.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha anunciado la aprobación de subvenciones de inducción para 33 nuevos empleados por su Junta Directiva el 25 de julio de 2024. Estas subvenciones, realizadas bajo la Regla de Listado NASDAQ 5635(c)(4), están fuera de los planes de incentivos de capital aprobados por los accionistas de la compañía. Las subvenciones permiten en conjunto a los nuevos empleados recibir hasta 60,900 unidades de acciones restringidas. Estas unidades se consolidarán anualmente durante un período de cuatro años, proporcionando un incentivo a largo plazo para que los nuevos empleados alineen sus intereses con el rendimiento de la empresa.
Arrowhead Pharmaceuticals (NASDAQ: ARWR)는 2024년 7월 25일 이사회에서 33명의 신규 직원에 대한 유인 보조금 승인을 발표했습니다. 이 보조금은 NASDAQ 상장 규칙 5635(c)(4) 아래에서 이루어지며, 회사의 주주 승인 자본 인센티브 계획 외부에서 제공됩니다. 이 보조금을 통해 신규 직원들은 최대 60,900개의 제한된 주식 단위를 받을 수 있게 됩니다. 이 단위는 4년 동안 매년 분배되어 신규 직원을 위한 장기적인 인센티브를 제공하여 회사의 성과와 그들의 이익을 일치시키도록 합니다.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) a annoncé l'approbation de subventions d'incitation pour 33 nouveaux employés par son Conseil d'Administration le 25 juillet 2024. Ces subventions, accordées en vertu de la Règle de Cotation NASDAQ 5635(c)(4), sont en dehors des plans d'incitation en actions approuvés par les actionnaires de l'entreprise. Les subventions permettent collectivement aux nouveaux employés de recevoir jusqu'à 60 900 unités d'actions restreintes. Ces unités s'acquitteront chaque année sur une période de quatre ans, offrant un incitatif à long terme pour les nouvelles recrues afin d'aligner leurs intérêts sur les performances de l'entreprise.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) hat am 25. Juli 2024 die Genehmigung von Induktionszuwendungen für 33 neue Mitarbeiter durch den Vorstand bekanntgegeben. Diese Zuwendungen erfolgen gemäß der NASDAQ-Notierungsregel 5635(c)(4) und liegen außerhalb der von den Aktionären genehmigten Kapitalanreizpläne des Unternehmens. Die Zuwendungen ermöglichen es den neuen Mitarbeitern insgesamt, bis zu 60.900 eingeschränkten Aktieneinheiten zu erhalten. Diese Einheiten vesten jährlich über einen Zeitraum von vier Jahren, was einen langfristigen Anreiz für die neuen Mitarbeiter bietet, ihre Interessen mit der Leistung des Unternehmens in Einklang zu bringen.
- Attraction of new talent with 33 new employees hired
- Long-term alignment of employee interests with company performance through 4-year vesting period
- Potential dilution of existing shareholders due to issuance of 60,900 new restricted stock units
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729420204/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
LifeSci Communications, LLC
Jason Braco, Ph.D.
646-751-4361
jbraco@lifescicomms.com
www.lifescicommunications.com
Source: Arrowhead Pharmaceuticals, Inc.
FAQ
How many new employees received inducement grants from Arrowhead Pharmaceuticals (ARWR)?
What type of equity awards were granted to new Arrowhead Pharmaceuticals (ARWR) employees?
What is the vesting schedule for the inducement grants issued by Arrowhead Pharmaceuticals (ARWR)?
Under which NASDAQ rule did Arrowhead Pharmaceuticals (ARWR) issue these inducement grants?
